Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
71.24
-0.61 (-0.85%)
At close: Jun 18, 2025, 4:00 PM
71.00
-0.24 (-0.34%)
After-hours: Jun 18, 2025, 6:03 PM EDT
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $157.21M in the quarter ending March 31, 2025, with 7.09% growth. This brings the company's revenue in the last twelve months to $685.45M, up 30.93% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$685.45M
Revenue Growth
+30.93%
P/S Ratio
10.76
Revenue / Employee
$1,370,892
Employees
500
Market Cap
7.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CORT News
- 5 days ago - Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring - Seeking Alpha
- 7 days ago - 20 stocks you should avoid — no matter how well the market does - Market Watch
- 13 days ago - Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - Business Wire
- 16 days ago - Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 6 weeks ago - Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Business Wire
- 7 weeks ago - CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire
- 2 months ago - CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire